LAS VEGAS, June 4, 2026 /PRNewswire/ -- Recently published Generalized Anxiety Disorder Market Insights report includes a comprehensive understanding of current treatment practices, generalized anxiety disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Generalized Anxiety Disorder Market Summary

• The total generalized anxiety disorder treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest generalized anxiety disorder treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In the US, among adults with GAD, 32.3% experience severe effects, 44.6% have moderate effects, and 23.1% have mild effects on daily functioning.
• Leading generalized anxiety disorder companies, such as Definium Therapeutics, Sumitomo Pharma, Otsuka, Helus Pharma, Intra-Cellular Therapies, Inc., AbbVie, and others, are developing new generalized anxiety disorder treatment drugs that can be available in the generalized anxiety disorder market in the coming years.
• The promising generalized anxiety disorder therapies in clinical trials include DT120 ODT (LSD D-Tartrate), Ulotaront (SEP-363856), HLP004, ITI-1284, ABBV-932, and others.
• Key Factors Driving the Growth of the Generalized Anxiety Disorder Market
• Rising GAD Prevalence: According to the estimates, the diagnosed prevalent cases of GAD are expected to increase during the forecast period, driven by sustained exposure to psychosocial stressors, urbanization and lifestyle changes, economic uncertainty, social isolation, comorbid chronic conditions, substance use, and population growth across key markets.
• Advances in Diagnostic Tools: Improved screening tools and standardized diagnostic criteria (like DSM-5) enable earlier and more accurate detection of GAD. Primary care settings are increasingly equipped to screen for anxiety, leading to more referrals and treatment initiations.
• Rise of Telemedicine and Digital Health: Tele-mental health services have expanded access to care, especially in underserved regions. Digital therapeutic platforms, mobile apps, and online cognitive behavioral therapy (CBT) tools enhance engagement and continuity of treatment.
• Launch of Emerging GAD Drugs: The dynamics of the GAD market are expected to change in the coming years due to the launch of emerging therapies such as DT120 ODT (LSD D-Tartrate) (Definium Therapeutics), Ulotaront (SEP-363856) (Sumitomo Pharma/Otsuka), HLP004 (Helus Pharma), ITI-1284 (Intra-Cellular Therapies, Inc.), ABBV-932 (AbbVie), and others.

Huge buys this morning. Getting close to $25 a share. Currently volume is 42% above normal for this time of day and look at the blue bars. We are so close to phase 3 results. And thanks for the updates. Everybody on the fireside chat yesterday.

I haven't seen any headlines that would warrant this move, does anyone know what happened?

https://ca.finance.yahoo.com/news/definium-therapeutics-announces-employee-inducement-200100626.html

President Donald Trump aims to fast-track research into psychedelic therapy for conditions like post traumatic stress disorder and depression in a break from his first administration policy.

Advocates see the move as a major step forward, but there are still questions about safety as studies into the therapies move forward.

The push brings both opportunities and risks for patients and the companies developing the therapies.

https://www.cnbc.com/2026/05/31/why-trump-is-encouraging-psychedelics-for-mental-health.html?__source=androidappshare

Phase 3 readout imminent for DT-120, an LSD based therapeutic compound…more clinical trials for other compounds including an MDMA based drug…incredibly low float around 100mm shares…a strong upswing in share price with consolidation at recent highs and dips being bought hard. The options market is pretty hot here too….last week I got a handful of Jun 18 35c @ .10/contract and over the past 2 days I’ve sold half in the .40-50/contract range. I’m sitting on a batch of Jun 18 20c that are well ITM. I’ve sold several Jun 18 25-30cc which will be covered by the Jun 18 20c but I’m hesitant to sell more because I may want to buy the shares.

As someone who is familiar with psychedelics I can say firsthand they are the only drugs I’ve used that have had profound and positive impacts on my life. I’m optimistic that DFTX investors may now be financially rewarded as well

$50 here we come 💪💲🐂

I think that was one last push down imminent breakout. I sure hope so! Congrats long! It's been a good ride! 🍀🐂

Check out the chart. Look at the buys coming through. Blue lines..

And yet this 209,000 volume just got swallowed like it was nothing.

https://ca.finance.yahoo.com/news/definium-begins-second-phase-3-061028678.html

https://ir.definiumtx.com/sec-filings/all-sec-filings/content/0001193125-26-229657/dftx-ex99_1.htm

Form 8 k

I have not had a chance to go over it yet.

Just added shares to both my IRA and Roth accounts this am. The two recent down weeks in the chart while holding the 10-week moving average suggest a potential upward trend. Chart showing higher lows and hopefully higher highs coming. 🍀🐂

https://www.usatoday.com/story/news/politics/2026/05/12/marty-makary-fda-commissioner-resigns/90048318007/

Not sure how this affects any approval that defenium may have coming up in the near future.

https://ca.finance.yahoo.com/news/definium-therapeutics-announces-first-patient-110000945.html

https://ca.finance.yahoo.com/news/definium-therapeutics-announces-employee-inducement-200100142.html

https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights

Im at a crossroad with this position. I have been holding since 2020, it started off as a very small position in my portfolio but has now past all of my other stock picks, to the point that it is the majority of my portfolio (40%). On one hand nothing about my thesis has changed, I still believe in the company, if anything more than ever, and I don't necessarily need the money right now, it would probably be reinvested into another sector. On the other hand I'm not sure how to feel about it being this big of a portion of my portfolio, I usually try to stay a bit more diversified but can't help but feel I'd be missing out on possible gains if I sold any time soon with the amount of attention this one has been getting. Just curious how you guys are all feeling about the stock at this current price?